Pharmaceutical Raw Material CAS 137071-32-0 Pimecrolimus Powder

Product Details
Customization: Available
Powder: Yes
Customized: Non-Customized
Still deciding? Get samples of $ !
Request Sample
Diamond Member Since 2021

Suppliers with verified business licenses

Audited Supplier

Audited by an independent third-party inspection agency

Registered Capital
10000000 RMB
Plant Area
101~500 square meters
  • Pharmaceutical Raw Material CAS 137071-32-0 Pimecrolimus Powder
  • Pharmaceutical Raw Material CAS 137071-32-0 Pimecrolimus Powder
  • Pharmaceutical Raw Material CAS 137071-32-0 Pimecrolimus Powder
  • Pharmaceutical Raw Material CAS 137071-32-0 Pimecrolimus Powder
  • Pharmaceutical Raw Material CAS 137071-32-0 Pimecrolimus Powder
  • Pharmaceutical Raw Material CAS 137071-32-0 Pimecrolimus Powder
Find Similar Products

Basic Info.

Model NO.
HNB-307
Certification
GMP, ISO 9001, USP, BP
Suitable for
Elderly, Children, Adult
State
Solid
Purity
>99%
Transport Package
Aluminium Foil Bag, Cardboard Drum
Trademark
HNB-Biotech
Origin
Shaanxi, China
Production Capacity
5000kg/Month

Product Description

Pharmaceutical Raw Material CAS 137071-32-0 Pimecrolimus Powder
Pharmaceutical Raw Material CAS 137071-32-0 Pimecrolimus Powder

Pharmaceutical Raw Material CAS 137071-32-0 Pimecrolimus Powder
Product name Pimecrolimus
Cas No. 137071-32-0
Molecular Formula C43H68ClNO11
Appearance White powder

Pimecrolimus is an immunophilin ligand, which binds specifically to the cytosolic receptor, immunophilin macrophilin-12.Target: OthersPimecrolimus blocks T-lymphocyte activation pathway by inhibiting calcineurin function. Pimecrolimus prevents the release of cytokines and pro-inflammatory mediators from mast cells. Pimecrolimus binds to macrophilin-12, the pimecrolimusmacrophilin complex then binds to the cytosolic enzyme calcineurin phosphatase. The pimecrolimus-macrophilin complex prevents the dephosphorylation of the cytoplasmic component of the nuclear factor of activated T cells by inhibiting the action of calcineurin. Pimecrolimus inhibits not only the transcription and synthesis of cytokines from mast cells, but also the release of preformed mediators serotonin and β-hexosaminidase by the inhibition of Fcε-RI-mediated degranulation and secretion.Pharmaceutical Raw Material CAS 137071-32-0 Pimecrolimus PowderPharmaceutical Raw Material CAS 137071-32-0 Pimecrolimus PowderPharmaceutical Raw Material CAS 137071-32-0 Pimecrolimus PowderPharmaceutical Raw Material CAS 137071-32-0 Pimecrolimus PowderPharmaceutical Raw Material CAS 137071-32-0 Pimecrolimus PowderPharmaceutical Raw Material CAS 137071-32-0 Pimecrolimus PowderPharmaceutical Raw Material CAS 137071-32-0 Pimecrolimus Powder
 

Send your message to this supplier

*From:
*To:
*Message:

Enter between 20 to 4,000 characters.

This is not what you are looking for? Post a Sourcing Request Now
Contact Supplier